Understanding the sources of efficacy dilution in a trial of a monthly dapivirine vaginal ring for HIV-1 prevention
International Journal of STD & AIDS · 2025
DOI: 10.1177/09564624241300199 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift International Journal of STD & AIDS, 2025. Verfasst von Kathryn Peebles und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA. Hauptthemen laut MEDLINE: HIV Infections, Pyrimidines, Contraceptive Devices, Female, HIV-1. Die Arbeit nennt 33 Literaturangaben. Gefördert von: NIH, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Introduction
Women-initiated HIV – 1 prevention products are key to reducing women’s HIV-1 risk. Clinical trials of vaginal microbicides have shown limited to no efficacy in intention-to-treat (ITT) analyses. It is hypothesized that these negative results are partly due to efficacy dilution.
Methods
We developed a microsimulation model of MTN-020/ASPIRE, a phase 3 trial that evaluated monthly use of a dapivirine vaginal ring for HIV-1 prevention. We evaluated four sources of efficacy dilution: trial-level factors: (i) an imbalance in the number of monthly sex acts between study arms and (ii) heterogeneity in risk emergent over time; and individual-level factors: (iii) product non-adherence and (iv) receptive anal intercourse.
Results
Assuming 70% per-vaginal exposure efficacy (consistent with the ITT estimate of 27%), heterogeneity in risk accounted for the largest proportion of efficacy dilution, at 42% (90% CrI: 38, 45), followed by non-adherence (33%; 90% CrI: 27, 39), an imbalance in arms (18%; 90% CrI: 16, 21) and lastly, anal intercourse with less than 10% of efficacy dilution.
Conclusion
Our results suggest that heterogeneity in risk was the most important source of efficacy dilution in the ASPIRE trial. Future trials of HIV-1 prevention products for women should consider alternative trial designs and analytic approaches that minimize bias introduced by heterogeneity in risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA.
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA.
- Department of Applied Mathematics, University of Washington, Seattle, WA, USA.
- Department of Global Health, University of Washington, Seattle, WA, USA.
- Department of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
- Wits RHI, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
ORCID-Profile: Laura Matrajt
Förderung
- NIH
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Peebles, K., Matrajt, L., Baeten, J. M., Palanee-Phillips, T., Brown, E. R., & MTN-020/ASPIRE Study Team (2025). Understanding the sources of efficacy dilution in a trial of a monthly dapivirine vaginal ring for HIV-1 prevention. International Journal of STD & AIDS. https://doi.org/10.1177/09564624241300199
Vancouver
Peebles K, Matrajt L, Baeten JM, Palanee-Phillips T, Brown ER, MTN-020/ASPIRE Study Team. Understanding the sources of efficacy dilution in a trial of a monthly dapivirine vaginal ring for HIV-1 prevention. International Journal of STD & AIDS. 2025. doi:10.1177/09564624241300199
BibTeX
@article{Peebles2025,
author = {Peebles, Kathryn and Matrajt, Laura and Baeten, Jared M and Palanee-Phillips, Thesla and Brown, Elizabeth R and MTN-020/ASPIRE Study Team, MTN-020/ASPIRE Study Team},
title = {Understanding the sources of efficacy dilution in a trial of a monthly dapivirine vaginal ring for HIV-1 prevention},
journal = {International Journal of STD & AIDS},
year = {2025},
doi = {10.1177/09564624241300199}
}
EUVIMED